Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) +/- goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy | Health & Environmental Research Online (HERO)

Health & Environmental Research Online (HERO)

Print Feedback Export to File

This record has one attached file:

Citation
Tags

HERO ID

6322155

Reference Type

Journal Article

Title

Phase 3, multicenter, randomized, double-blind, placebo-controlled trial of fulvestrant with or without PD-0332991 (palbociclib) +/- goserelin in women with hormone receptor-positive, HER2-negative metastatic breast cancer (MBC) whose disease progressed after prior endocrine therapy

Author(s)

Turner, N; Andre, F; Loibl, S; Ro, J; Iwata, H; Harbeck, N; Glueck, S; Verma, S; Loi, S; Bartlett, CH; Thiele, A; Zhang, K; Koehler, M; Cristofanilli, M

Year

2013

Is Peer Reviewed?

Yes

Journal

Cancer Research
ISSN: 0008-5472
EISSN: 1538-7445

Volume

DOI

10.1158/0008-5472.SABCS13-T3-2-10

Web of Science Id

WOS:000209496900098